KIR3DL2 | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Trial results

21 March 2024

Innate gets a new lacutamab blow

Green traffic light

Regulatory

4 January 2024

Lacutamab lift boosts Innate

Conferences Trial results

10 December 2023

ASH 2023 – lacutamab’s late-line promise on hold

Subscribe to KIR3DL2